Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus BUDESONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR DIGIHALER versus BUDESONIDE.
ARMONAIR DIGIHALER vs BUDESONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARMONAIR DIGIHALER contains fluticasone furoate and umeclidinium, and vilanterol. Fluticasone furoate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, modulating gene expression to reduce inflammatory mediators. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine at M3 receptors, causing bronchodilation. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates beta2 receptors, leading to smooth muscle relaxation and bronchodilation.
Budesonide is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting pro-inflammatory cytokines and leukocyte migration.
2 inhalations (55 mcg each) orally twice daily for maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD).
Inhaled: 400-800 mcg/day in 2 divided doses for asthma; oral controlled ileal release: 9 mg once daily for Crohn's disease; intranasal: 256 mcg/day in 2 sprays per nostril once daily for allergic rhinitis.
None Documented
Clinical Note
moderateBudesonide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin."
Clinical Note
moderateBudesonide + Rosoxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin."
Clinical Note
moderateBudesonide + Levofloxacin
"The risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin."
Clinical Note
moderateBudesonide + Trovafloxacin
None Documented
Terminal elimination half-life of unchanged arformoterol is approximately 26 hours (range 21-30 hours). This supports twice-daily dosing with approximately 2 days to steady state.
2-3.6 hours (terminal elimination half-life); due to high hepatic clearance, systemic half-life is short, limiting systemic exposure.
Renal: approximately 70% as unchanged drug; biliary/fecal: approximately 30%
Primarily hepatic metabolism via CYP3A4; metabolites excreted in feces (~60%) and urine (~10-15%). Renal excretion of unchanged drug is negligible (<2%).
Category C
Category A/B
Inhaled Corticosteroid
Inhaled Corticosteroid
"The risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin."